Allergy treatment never ends.
We’re working on something that does.
AbstimX™: A patented two-antibody approach designed to restore immune regulation.
Nixxie, age 6
Treatment. Repeat.
Daily pills. Monthly injections. Years of therapy.
Modern treatments can work extremely well. But much of allergy care is built around ongoing suppression.
What if treatment could be finite?
A massive category built around maintenance.
$17.8B
2025 global sales of a leading allergy and immunology therapy
Allergic and inflammatory diseases already support some of the world’s largest therapeutic franchises.
The opportunity is not another maintenance drug.
It is a different treatment model.
Two antibodies.
One different idea.
Combining two established human immunoglobulin components in a patented investigational regimen.
Rather than continuously blocking one part of the allergic response, it is designed to work with the immune system’s own regulatory biology.
Finite course. Upstream approach. Still being proven.
From manage the response,
To Restore regulation.
Current therapy is largely built around controlling the allergic response.
AbstimX™ is designed to influence the regulation upstream.
The components aren’t new.
The combination is.
Human immunoglobulin products have decades of clinical use. NI’s patented combination and therapeutic approach are new.
Granted patents in the US, China and Japan
The final treatment regimen remains under development.
Where we are
Patent estate
Granted in the US, China and Japan
Published preclinical evidence
Six peer-reviewed publications across two species
Canine clinical pilot study
Underway at an independent academic centre - data arriving 2027
Further Product definition
Specification, manufacturing, supply and cost
Human studies
Preparing
AbstimX™ is investigational. Efficacy in humans has not been established.
